# Citicoline in Ischemic Stroke

Study · id `cardio:ct-nct05154903` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05154903](<https://clinicaltrials.gov/study/NCT05154903>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05154903

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05154903. Randomized; no masking; primary purpose treatment. Start 2021-07-22 (actual); primary completion 2022-04-22 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05154903, source copy `cardio:ctgov-nct05154903-2022-02-17`, retrieved 2026-10-26)
- Started: 2021-07-22 (actual) (ClinicalTrials.gov record NCT05154903, source copy `cardio:ctgov-nct05154903-2022-02-17`, retrieved 2026-10-26)
- Primary completion: 2022-04-22 (anticipated) (ClinicalTrials.gov record NCT05154903, source copy `cardio:ctgov-nct05154903-2022-02-17`, retrieved 2026-10-26)
- Completion: 2022-06-22 (anticipated) (ClinicalTrials.gov record NCT05154903, source copy `cardio:ctgov-nct05154903-2022-02-17`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT05154903, source copy `cardio:ctgov-nct05154903-2022-02-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05154903-2022-02-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Citicoline in Ischemic Stroke
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Citicoline 500 MG
- Lead sponsor: Ain Shams University
- Lead sponsor class: OTHER
- Collaborator: Kafrelsheikh University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Ain Shams University (`cardio:org-ain-shams-university`)
- Registry lists this organization as a collaborator: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

## Provenance

Content hash: 43423bc941aa9766c5d37c4737ff1dfb4b7bad709bfe375b2337ecd47c692d25
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
